Paxlovid Boceprevir Intermediate CAS 565456-77-1 Assay ≥99.0%

Nkọwa dị mkpirikpi:

Aha: (1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride

Nọmba: 565456-77-1

Ọdịdị: White ka Gbanyụọ-Ọcha ntụ ntụ

Nyocha: ≥99.0%

Ọkara nke PF-07321332 Paxlovid (CAS 2628280-40-8) na Boceprevir (CAS 394730-60-0)

Ogo dị elu, mmepụta azụmahịa

Inquiry: alvin@ruifuchem.com


Nkọwa ngwaahịa

Ngwaahịa ndị emetụtara

Mkpado ngwaahịa

Nkọwa:

Njirimara kemịkalụ:

Aha Chemical (1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride
Ụdị okwu Methyl (1R,2S,5S) -6,6-dimethyl-3-azabicyclo[3.1.0] hexane-2-carboxylate Hydrochloride
Nọmba CAS 565456-77-1
Nọmba CAT RF-PI318
Ọnọdụ Ahịa N'ọkwa, Mpụta Ihe ruru Tọn
Usoro ihe omimi C9H15NO2.ClH
Ibu molekụla 205.683
Ụdị Ruifu Chemical

Nkọwapụta:

Ihe Nkọwapụta
Ọdịdị Ọcha ka Gbanyụọ-Ọcha ntụ ntụ
njirimara A IR: Yiri ihe ntụaka
njirimara B Oge njide: Yiri ihe ntụaka
Entiomer ≤0.15%
adịghị ọcha emetụtara (nke HPLC)
Adịghị ọcha amaghi ama ≤0.20%
Mgbakọta adịghị ọcha ≤1.0%
Mmiri ≤0.50%
Ihe fọdụrụ na mgbanye ≤0.10%
Ọla dị arọ ≤20ppm
Nyocha ≥99.0%
Nlele ọkọlọtọ Standardkpụrụ ụlọ ọrụ
Ojiji Ọkara nke PF-07321332 Paxlovid (CAS 2628280-40-8) na Boceprevir (CAS 394730-60-0)

Ngwungwu & Nchekwa:

ngwugwu: Kalama, Aluminom foil bag, kaadiboodu drum, 25kg / Drum, ma ọ bụ dị ka ndị ahịa chọrọ.

Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ọkụ, mmiri mmiri na ụmụ ahụhụ.

Uru:

1

Ajụjụ:

Ngwa:

(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride (CAS 565456-77-1) bụ azabicyclohexane ewepụtara eji na nkwadebe nke ịba ọcha n'anya C. nje virus (HCV) NS3 serine protease inhibitor.Ọ bụ etiti nke PF-07321332 Paxlovid (CAS 2628280-40-8) na Boceprevir (CAS 394730-60-0).PF-07321332 bụ onye na-egbochi SARS-CoV 3C dị ka protease (3CLPRO) na-arụ ọrụ.PF-07321332 lekwasịrị anya na nje SARS-CoV-2 ma enwere ike iji ya mee nyocha COVID-19.Boceprevir (INN, ahia aha Victrelis) bụ protease inhibitor eji dị ka ọgwụgwọ maka ịba ọcha n'anya C genotype 1. Ọ na-ejikọta HCV nonstructural 3 NS3 (HCV) saịtị nọ n'ọrụ.Ọ bụ Schering-Plough na-emepụta ya, mana Merck na-emepụta ya ugbu a ebe ọ bụ na e nwetara Schering na 2009. FDA kwadoro ya na May 13, 2011.

Dee ozi gị ebe a ziga anyị ya